secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001562762-24-000195
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%
----------------------------------------------------------------------------

- Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.
- GAAP diluted EPS $0.23; non-GAAP diluted EPS $0.75, up 20% vs $0.63 prior year.
- Non-GAAP adjusted EBITDA $190.4M (30.2% of sales); operating cash flow $54.3M, FCF $26.5M.
- Raised FY2024 revenue guidance to $2.47B-$2.49B; non-GAAP EPS $2.80-$2.90.
- Growth driven by NuVasive acquisition, spine product volume, enabling technology sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/0001562762-24-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/gmed-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer